MacroGenics, Inc. (NASDAQ:MGNX) – Investment analysts at Leerink Swann lifted their FY2017 earnings per share (EPS) estimates for shares of MacroGenics in a report released on Thursday. Leerink Swann analyst M. Schmidt now forecasts that the biopharmaceutical company will earn ($0.77) per share for the year, up from their previous forecast of ($4.69). Leerink Swann also issued estimates for MacroGenics’ Q4 2017 earnings at $2.60 EPS and FY2018 earnings at ($5.69) EPS.
A number of other research analysts have also weighed in on the stock. ValuEngine lowered shares of MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Tuesday. Citigroup Inc. boosted their target price on shares of MacroGenics from $18.00 to $22.00 and gave the stock a “neutral” rating in a research report on Friday. Cowen and Company reissued a “buy” rating on shares of MacroGenics in a research report on Wednesday, October 25th. Zacks Investment Research raised shares of MacroGenics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $34.00 price objective on shares of MacroGenics in a research report on Tuesday, September 12th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $30.10.
COPYRIGHT VIOLATION WARNING: This news story was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/11/14/leerink-swann-comments-on-macrogenics-inc-s-fy2017-earnings-mgnx.html.
MacroGenics (MGNX) opened at $17.85 on Monday. MacroGenics has a 52-week low of $14.36 and a 52-week high of $31.85.
MacroGenics (NASDAQ:MGNX) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.09) by ($0.19). The firm had revenue of $1.70 million for the quarter, compared to analyst estimates of $5.50 million. MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The firm’s revenue was down 48.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.97) EPS.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc increased its stake in MacroGenics by 4.3% in the second quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 328 shares during the period. Ameriprise Financial Inc. increased its stake in MacroGenics by 1.0% in the first quarter. Ameriprise Financial Inc. now owns 49,059 shares of the biopharmaceutical company’s stock valued at $912,000 after acquiring an additional 485 shares during the period. The Manufacturers Life Insurance Company increased its stake in MacroGenics by 2.9% in the second quarter. The Manufacturers Life Insurance Company now owns 26,485 shares of the biopharmaceutical company’s stock valued at $463,000 after acquiring an additional 743 shares during the period. Cornerstone Capital Management Holdings LLC. increased its stake in MacroGenics by 3.8% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 23,238 shares of the biopharmaceutical company’s stock valued at $406,000 after acquiring an additional 848 shares during the period. Finally, Jennison Associates LLC increased its stake in MacroGenics by 0.6% in the second quarter. Jennison Associates LLC now owns 189,970 shares of the biopharmaceutical company’s stock valued at $3,326,000 after acquiring an additional 1,062 shares during the period. 84.72% of the stock is currently owned by institutional investors and hedge funds.
In related news, SVP Jon Marc Wigginton sold 10,000 shares of the company’s stock in a transaction dated Wednesday, October 25th. The shares were sold at an average price of $20.00, for a total value of $200,000.00. Following the sale, the senior vice president now owns 40,000 shares of the company’s stock, valued at $800,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 8.30% of the company’s stock.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.